| Title |
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, April 2019
|
| DOI | 10.1007/s00432-019-02894-3 |
| Pubmed ID | |
| Authors |
Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Dragana Milojkovic, Philipp le Coutre, Valentin Garcia-Gutierrez, Rocco Crescenzo, Carla Mamolo, Arlene Reisman, Andreas Hochhaus, Tim H. Brümmendorf |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 75% |
| Peru | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 10% |
| Student > Doctoral Student | 4 | 10% |
| Other | 2 | 5% |
| Student > Ph. D. Student | 2 | 5% |
| Professor > Associate Professor | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 19 | 49% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 15% |
| Nursing and Health Professions | 2 | 5% |
| Unspecified | 1 | 3% |
| Physics and Astronomy | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 19 | 49% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2019.
All research outputs
#7,849,067
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#601
of 2,632 outputs
Outputs of similar age
#141,716
of 352,820 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#13
of 38 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.